Vertex Pharmaceuticals Incorporated just experienced a notable drop in its market position. Investors are buzzing, trying to ...

Vertex Pharmaceuticals Incorporated faces a dynamic landscape with its innovative approach in the pharmaceutical industry. As challenges mount in a competitive sector, the company taps into its ...

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most ...

DM1 results from a CTG repeat expansion in the DMPK gene, with disease severity linked to the number of repeats (symptoms ...

Trinasolar, a global leader in solar technology and energy storage solutions, will showcase the next chapter of its U.S. innovation at RE+ ...

Vertex is a reasonably priced stock with a lot of potential upside According to analyst estimates, Vertex's stock is trading at 22 times its projected future earnings.

A federal judge ruled Hampton’s Zoning Board had ample evidence to reject the tower, but left one legal claim standing.

Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.

Vertex Pharmaceuticals nosedived on Tuesday to hit a new all-time low following the termination of a clinical trial for an experimental pain medicine.

Such steep sell-offs can sometimes present great buying opportunities. I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

Vertex Pharmaceuticals shares fell 18.8% to trade at $383.40 on Tuesday. These analysts made changes to their price targets on Vertex Pharmaceuticals following earnings announcement.